Symbols

Symbols

BFRI

BFRI

Biofrontera shares fall 11.21% intraday after Xepi license divestiture raises concerns over contingent revenue and financial stability.

Pelthos Therapeutics Acquires Xepi, Expands Dermatology Portfolio

Biofrontera shares rise 12.5% premarket after selling Xepi U.S. license to Pelthos for up to $10M.

Biofrontera receives $10mln from Xepi divestment, bolsters cash position.

Biofrontera Sells Xepi License to Pelthos for Up to $10M

Biofrontera Licenses Xepi Antibiotic Cream to Pelthos for Up to $10M, Bolstering Cash Position.

Thursday Oct 23, 2025

Biofrontera Closes Ameluz and RhodoLED Acquisition, Reduces Earnout to 12%-15% of US Net Sales

Friday Sep 26, 2025

Biofrontera to present at Lytham Partners Fall 2025 Investor Conference.

Biofrontera to Present at Lytham Partners Fall 2025 Investor Conference

Wednesday Sep 24, 2025

Biofrontera Inc. shares rise 4.20% premarket after engaging Lytham Partners for strategic investor relations.

Tuesday Sep 23, 2025

Biofrontera engages Lytham Partners for strategic investor relations and communication.

Biofrontera Inc. Engages Lytham Partners for Strategic Investor Relations and Shareholder Communication.

Tuesday Sep 16, 2025

Biofrontera Completes Phase 3 Trial for Ameluz PDT in Actinic Keratoses

Biofrontera Announces Completion of Phase 3 Trial for Ameluz PDT Treatment of Actinic Keratoses on Extremities, Neck and Trunk.

Tuesday Sep 02, 2025

Biofrontera Posts Record Sales, Strategic Independence Amid Net Losses

Tuesday Aug 26, 2025

Biofrontera Completes Last Patient in Phase 2b Study for Ameluz Topical Gel

Monday Aug 25, 2025

Biofrontera reaches final patient visit for acne treatment trial.

Friday Aug 15, 2025

Biofrontera Q2 Revenue Rises 15%, Company Restructures Amidst Patent Extension and Clinical Trials

Biofrontera Remains a Buy According to Benchmark Co. Analyst Bruce Jackson

Thursday Aug 14, 2025

Biofrontera Reports Record-Breaking Performance Driven by Strategic Shifts